M. Andrea

Prognostic impact of rapid reduction of involved free light chains in multiple myeloma patients under first-line treatment with Bendamustine, Prednisone, and Bortezomib (BPV)

M. Scholz, U. Platzbecker, S. Schwind, 2021, Journal of Cancer Research and Clinical Oncology.

Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone

D. Niederwieser, T. Lindner, W. Pönisch, 2012, Journal of Cancer Research and Clinical Oncology.

Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV)

D. Niederwieser, R. Krahl, S. Schwind, 2017, Journal of Cancer Research and Clinical Oncology.

Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure

D. Niederwieser, T. Lindner, R. Krahl, 2013, Journal of Cancer Research and Clinical Oncology.

Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma

G. Behre, D. Niederwieser, T. Lindner, 2014, Journal of Cancer Research and Clinical Oncology.

Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma

D. Niederwieser, S. Schwind, T. Lange, 2015, Journal of Cancer Research and Clinical Oncology.

Successful Treatment with Bortezomib in Combination with Bendamustine and Prednisone of Patients with Newly Diagnosed/Untreated Multiple Myeloma and Light Chain Induced Renal Failure

D. Niederwieser, T. Lindner, W. Pönisch, 2011 .

Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077)

J. Beck, D. Niederwieser, S. Schwind, 2017, Journal of Cancer Research and Clinical Oncology.